Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tieghemella heckelii hydroethanolic leaf extract is a botanical preparation derived from the leaves of the *Tieghemella heckelii* tree, commonly known as Baku or Cherry Mahogany, which is indigenous to the rainforests of West and Central Africa. While the plant's stem bark has a history of traditional medicinal use, recent scientific investigation has pivoted toward the leaves to evaluate their therapeutic potential. Research indicates that the hydroethanolic extract possesses significant in vitro cytotoxic properties against several human malignancy models, including breast cancer (MDA-MB-468), liver cancer (HepG2), and prostate cancer (PC3) cell lines. The extract is thought to contain bioactive phytochemicals that interfere with cancer cell viability, although the specific molecular pathways and active constituents responsible for these effects are still under investigation in the preclinical stage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tieghemella heckelii hydroethanolic leaf extract.